Central Lakes Chiropractic Clinic Pc Chiropractor Medicare: Medicare Enrolled Practice Location: 510 22nd Ave E, Suite 701, Alexandria, MN 56308 Phone: 320-763-9711 Fax: 320-763-9707 |
Dr. Bjorn Hurlen, D.C. Chiropractor Medicare: Medicare Enrolled Practice Location: 614 Hawthorne St, Alexandria, MN 56308 Phone: 320-762-2309 Fax: 320-762-2300 |
Touching Lives Chiropractic, P.c. Chiropractor Medicare: Medicare Enrolled Practice Location: 303 West 22nd Avenue, Suite 100, Alexandria, MN 56308 Phone: 320-846-9600 Fax: 320-846-9601 |
Life Quest Chiropractic & Sports Chiropractor Medicare: Medicare Enrolled Practice Location: 123 3rd Ave E, Suite 100, Alexandria, MN 56308 Phone: 320-762-0683 Fax: 320-762-1278 |
Kristen Lingl, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1804 Broadway St, Alexandria, MN 56308 Phone: 320-763-0313 Fax: 320-763-4635 |
Dr. Jon Michael Godfrey, D.C. Chiropractor - Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 119 6th Ave E, Alexandria, MN 56308 Phone: 320-762-8185 Fax: 320-762-8186 |
Heinz Family Chiropractic Pa Chiropractor Medicare: Medicare Enrolled Practice Location: 1698 N Nokomis St Ne, Alexandria, MN 56308 Phone: 320-763-3333 |
News Archive
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence has issued a positive Appraisal Consultation Document on ILUVIEN for the treatment of pseudophakic patients with chronic diabetic macular edema considered insufficiently responsive to available therapies.
Jackson Health System in Florida is trying to boost profitable services but faces one overwhelming challenge, They don't know which procedures make money, The Miami Herald reports.
Children with autism have a different chemical fingerprint in their urine than non-autistic children, according to new research published tomorrow in the print edition of the Journal of Proteome Research.
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
HRL Laboratories, LLC, in collaboration with University of New Mexico, have published the first study showing that transcranial alternating current stimulation of the brain during sleep increases human subjects' ability to accurately assess hidden targets in novel visual scenes.
› Verified 8 days ago